Breakthrough in Pediatric Leukemia Treatment
A landmark clinical trial in India has demonstrated that a simple change in steroid administration—giving steroids in short bursts instead of continuously—can halve early treatment-related deaths in children with acute lymphoblastic leukemia (ALL) without compromising their chances of being cured. The study, led by the Indian Childhood Collaborative Leukemia (ICiCle) group and involving researchers from the University of Manchester, treated over 3,000 children with acute B-cell precursor ALL at six major centers across India.
ALL is a fast-growing blood cancer that originates from very early B-cells in the bone marrow. It is the most common form of leukemia in children. The findings, published in The Lancet Regional Health—Southeast Asia, compared the standard four-week continuous steroid course with a pulsed schedule given in weeks one, two, and four.
Key Findings: Reduced Mortality, Maintained Efficacy
Children on the pulsed schedule experienced significantly fewer early deaths, with mortality rates falling from 3.5% to 1.3%. Most leukemia-related early deaths are currently caused by severe infections linked to continuous steroid use—a major challenge in low- and middle-income countries. Crucially, the shorter steroid exposure did not affect how well the treatment worked, with remission rates of around 98% in both groups. Survival outcomes were also similar, showing that the safer approach does not compromise cure.
The trial also found that using a powerful class of chemotherapy drugs called anthracyclines early in treatment increased the risk of treatment-related deaths. This finding underscores the need for careful timing and selection of chemotherapy agents in pediatric leukemia protocols.
Context: Global Disparities in Childhood Leukemia Survival
Childhood leukemia now has survival rates above 90% in many wealthy countries. However, children in low- and middle-income countries still face far higher risks of dying during treatment, often because infections strike early on. The ICiCle-ALL-14 trial is the first multicenter randomized pediatric oncology trial conducted in India, marking a significant step toward addressing these disparities.
Since 2013, the ICiCle group has been working to bring a consistent, modern treatment approach to children with leukemia across India, rolled out to centers nationwide. Professor Vaskar Saha from the University of Manchester and Tata Medical Center, lead author and founder of the ICiCle group, stated, "We show for the first time that a simple modification to steroid dosing can dramatically reduce early deaths without affecting cure rates. This has the potential to save thousands of lives in resource-limited settings."
Implications for Global Pediatric Oncology
The results of this trial have immediate implications for clinical practice in low- and middle-income countries, where the burden of childhood leukemia is high and resources are limited. By adopting a pulsed steroid schedule, hospitals can reduce early mortality without additional cost or complex interventions. The study also highlights the importance of conducting rigorous clinical trials in diverse settings to ensure that treatments are optimized for local conditions.
The ICiCle group plans to expand its efforts to other centers and explore further modifications to treatment protocols that could improve outcomes for children with leukemia worldwide.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
